placebo in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COVACTA (Rosas), 2020 (REV) 0.98 [0.59; 1.62]
NCT04377750 (HMO-0224-20), 0 (REV) 2.08 [0.65; 6.72]
Rosas (REMDACTA), 2021 (REV) 1.05 [0.72; 1.54]
1.07 [0.80 ; 1.44 ] COVACTA (Rosas), 2020 (REV), NCT04377750 (HMO-0224-20), 0 (REV), Rosas (REMDACTA), 2021 (REV) 3 0% 1,132 moderate not evaluable deathsdetailed results COVACTA (Rosas), 2020 (REV) 0.86 [0.54; 1.36]
NCT04377750 (HMO-0224-20), 0 (REV) 2.08 [0.65; 6.72]
Rosas (REMDACTA), 2021 (REV) 1.05 [0.72; 1.54]
1.02 [0.76 ; 1.35 ] COVACTA (Rosas), 2020 (REV), NCT04377750 (HMO-0224-20), 0 (REV), Rosas (REMDACTA), 2021 (REV) 3 0% 1,146 moderate not evaluable deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 (REV) 0.86 [0.54; 1.36]
Rosas (REMDACTA), 2021 (REV) 1.05 [0.72; 1.54]
0.97 [0.72 ; 1.30 ] COVACTA (Rosas), 2020 (REV), Rosas (REMDACTA), 2021 (REV) 2 0% 1,092 moderate not evaluable clinical improvementdetailed results COVACTA (Rosas), 2020 (REV) 0.84 [0.57; 1.24]
0.84 [0.57 ; 1.24 ] COVACTA (Rosas), 2020 (REV) 1 0% 438 NA not evaluable clinical improvement (28-day)detailed results COVACTA (Rosas), 2020 (REV) 0.84 [0.57; 1.24]
0.84 [0.57 ; 1.24 ] COVACTA (Rosas), 2020 (REV) 1 0% 438 NA not evaluable death or ventilationdetailed results Rosas (REMDACTA), 2021 (REV) 1.02 [0.75; 1.39]
1.02 [0.75 ; 1.39 ] Rosas (REMDACTA), 2021 (REV) 1 0% 649 NA not evaluable hospital dischargedetailed results Rosas (REMDACTA), 2021 (REV) 1.03 [0.83; 1.27]
1.03 [0.83 ; 1.27 ] Rosas (REMDACTA), 2021 (REV) 1 0% 649 NA not evaluable mechanical ventilationdetailed results COVACTA (Rosas), 2020 (REV) 1.50 [0.88; 2.56]
1.50 [0.88 ; 2.56 ] COVACTA (Rosas), 2020 (REV) 1 0% 273 NA not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 (REV) 2.08 [1.07; 4.04]
2.08 [1.07 ; 4.04 ] COVACTA (Rosas), 2020 (REV) 1 0% 191 NA not evaluable serious adverse eventsdetailed results COVACTA (Rosas), 2020 (REV) 1.23 [0.82; 1.85]
Rosas (REMDACTA), 2021 (REV) 1.20 [0.85; 1.71]
1.21 [0.93 ; 1.58 ] COVACTA (Rosas), 2020 (REV), Rosas (REMDACTA), 2021 (REV) 2 0% 1,080 moderate not evaluable adverse eventsdetailed results COVACTA (Rosas), 2020 (REV) 1.16 [0.69; 1.94]
Rosas (REMDACTA), 2021 (REV) 0.76 [0.53; 1.09]
0.90 [0.60 ; 1.34 ] COVACTA (Rosas), 2020 (REV), Rosas (REMDACTA), 2021 (REV) 2 41% 1,080 moderate not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-09 03:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
